Insulet Co. (NASDAQ:PODD) Receives Average Rating of "Moderate Buy" from Brokerages

Insulet Co. (NASDAQ:PODD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seventeen brokerages that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $306.53.

A number of brokerages have commented on PODD. Canaccord Genuity Group upped their price target on Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Barclays increased their target price on shares of Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Piper Sandler raised their target price on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Oppenheimer lifted their price target on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Finally, Raymond James reissued an "outperform" rating and issued a $328.00 price objective (up from $294.00) on shares of Insulet in a research note on Friday, February 21st.

Insulet Stock Performance

PODD stock traded down $2.97 during midday trading on Friday, reaching $324.50. 653,394 shares of the company's stock traded hands, compared to its average volume of 707,851. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet has a 52-week low of $170.67 and a 52-week high of $329.50. The stock has a market cap of $22.84 billion, a P/E ratio of 56.05, a PEG ratio of 3.62 and a beta of 1.26. The stock's 50-day moving average is $267.35 and its 200 day moving average is $267.99.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.73 EPS. As a group, analysts anticipate that Insulet will post 3.92 EPS for the current year.

Insider Buying and Selling at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president now directly owns 23,180 shares in the company, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now owns 3,231 shares of the company's stock, valued at $888,525. This represents a 36.10% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Larson Financial Group LLC lifted its position in Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 81 shares during the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of Insulet during the 1st quarter valued at about $26,000. SouthState Corp raised its position in shares of Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 76 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Insulet in the 4th quarter valued at about $36,000. Finally, Itau Unibanco Holding S.A. purchased a new position in Insulet in the fourth quarter worth about $42,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.